Company record
Pathos AI
Updated October 24, 2026 · Presspool
A clinical-stage AI and technology company advancing its own therapeutic pipeline of drugs. pathos.com
Funding
Latest announced financing: $237 million, Series E, led by Bristol Myers Squibb, announced October 23, 2026.
- $237 million Series E, announced October 23, 2026. Led by Bristol Myers Squibb. Post-money valuation is about $3 billion, per the announcement. Listed in the AI startup funding roster for October 18–24, 2026. Sources: Pathos AI announcement, Fierce Biotech.
Of the 5 Series E rounds announced in dollars on Presspool's weekly rosters since September 21, 2026, Pathos AI's $237 million is the smallest; their median is $311 million.
Whether AI names Pathos AI
- Machine Relations Index: Not cited in any Machine Relations Index answer, May 10, 2026 to October 24, 2026.
Related records
Closest rounds in the roster for October 18–24, 2026: Pigment ($250 million Series E, October 21, 2026), Legora ($550 million Series E, October 21, 2026), doubleAI ($200M Series A, October 19, 2026), ASI ($325 million Series C, October 20, 2026), Arda Industries ($160 million Series A, October 20, 2026), Eka Robotics ($150M Series A, October 20, 2026).